Current Perspectives on Long-term Obesity Pharmacotherapy

Area of Science:

• Endocrinology
• Pharmacology
• Public Health

Background:

• Obesity affects approximately 25% of Canadian adults, elevating risks for type 2 diabetes, cardiovascular disease, and hypertension.
• Current guidelines recommend 5%-10% weight loss for risk reduction, but lifestyle management alone has limited long-term success.
• Bariatric surgery offers significant weight loss but has strict BMI criteria and long waiting times.

Purpose of the Study:

• To review current and emerging pharmacotherapies for long-term obesity management.
• To discuss mechanisms, clinical features, and Canadian availability of obesity medications.
• To provide an overview of treatments for individuals struggling with weight loss.

Main Methods:

• Review of existing literature on obesity pharmacotherapies.
• Summary of mechanisms of action for novel antiobesity medications (e.g., reducing calorie intake, increasing satiety).
• Analysis of long-term weight loss data and treatment guidelines.

Main Results:

• Two long-term obesity pharmacotherapies, liraglutide and orlistat, are currently approved in Canada.
• Novel therapies target energy intake, satiety, hunger, and calorie absorption.
• Significant weight loss (≥5%) within 12 weeks often predicts long-term efficacy and continued use.

Conclusions:

• Pharmacotherapy represents a significant advancement in obesity management.
• These medications offer a viable alternative or adjunct to lifestyle changes and bariatric surgery.
• Ongoing research and development promise further innovations in obesity pharmacotherapy.